ARC Intellicare for Telerehabilitation
ARC Intellicare for Telerehabilitation in Neurological Patients
We could not find results for this trial
What it found
We found no results in the registry or in papers.
This trial finished 3 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- ARC Intellicare
Compared with
- Rehabilitation sheets
What it measured
Main measures
Efficacy outcome: Six minutes walking test (6MWT)
8 weeks
Walking and mobilityEfficacy outcome: Borg scale
8 weeks
safety outcome: adverse event frequency
8 weeks
SafetyUsability outcome: adherence to prescription
8 weeks
Quality of life (reported by participants)
Who could take part
MS (type not specified) · 18 to 75
Show the full criteria
Inclusion criteria
* patients with diagnosis of Parkinson's disease with Hoehn\&Yahr staging 1-3 * diagnosis of multiple sclerosis with extended disability scale score 3.5-6 * diagnosis of ischemic stroke in the past 12 months
Exclusion criteria
* history of falls * dementia * epilepsy
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
In the last 5 years, the available literature evidence has indicated that, in terms of clinical efficacy, telerehabilitation can give comparable results compared to face-to-face rehabilitation. Studies of post-stroke patients have revealed some benefits of telerehabilitation, such as the ability for patients to self-record pain, mood and activity. Telerehabilitation has comparable efficacy to face-to-face rehabilitation for the recovery of some abilities, such as motor function, Activities of Daily Living (ADL), and independence; it is less effective, however, for the recovery of balance control. Published reviews concerning, in particular, neurological/neurodegenerative diseases show that telerehabilitation systems are effective in maintaining and/or improving some motor aspects, such as balance and gait, and non-motor aspects, such as mood and quality of life; they also increase patient satisfaction, so in the long term they appear to be beneficial, convenient and satisfying for patients and operators. ARC Intellicare is a device undergoing certification as a Class I Medical Device (DM), already clinically tested during two uncontrolled clinical feasibility studies: ARCANGEL study (post-stroke, ClinicalTrials.gov Identifier: NCT03787433) and RICOMINCIARE study (post-COVID19 and Parkinson's disease, ClinicalTrials.gov Identifier: NCT05074771).
Papers
Loading reviews and guidelines…
History
Started
Jan 2023
Main results due
Sept 2023
Finished
Dec 2023